Skip to main content
Jon Cuthbert Profile pIcture
Jon Cuthbert

Jon Cuthbert

GrafaFounder & COO

Jon is a former international magazine editor with a strong background in business publications (print and digital) in the Middle East and Australia.

Articles by Jon Cuthbert

Grafa

Bristol Myers drug halves risk of myeloma progression in pivotal trial

Bristol Myers Squibb (NYSE:BMY) announced positive late-breaking results from its Phase 3 SUCCESSOR-2 clinical trial, demonstrating that its experimental oral therapy mezigdomide significantly extends the time patients with relapsed or refractory multiple myeloma live without their disease worsening.

Read more: Bristol Myers drug halves risk of myeloma progression in pivotal trial
Grafa

Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.

Read more: Agios discontinues tebapivat program in lower-risk myelodysplastic syndromes after Phase 2b trial fails
Grafa
Oil and Gas

Oil steadies near $94 but heads for steepest weekly loss since April on Iran deal hopes

Oil prices stabilized on Friday but remained on track for their sharpest weekly decline since early April, as investors weighed reports of a tentative ceasefire extension between the U.S. and Iran against a backdrop of lingering political hurdles.

Read more: Oil steadies near $94 but heads for steepest weekly loss since April on Iran deal hopes